J Clin Neurol.  2009 Mar;5(1):24-28.

Long-Term Durability of Percutaneous Transluminal Angioplasty in Patients with Symptomatic Middle Cerebral Artery Stenosis

• Kim JT
• Lee SH
• Choi SM
• Park MS
• Kim BC
• Yoon W
• Kim JK
• Kim MK
• Cho KH

Abstract

BACKGROUND AND PURPOSE: Percutaneous transluminal angioplasty (PTA) is being increasingly used in the treatment of symptomatic middle cerebral artery (MCA) stenosis. We evaluated the long-term durability after PTA for symptomatic MCA stenosis.
METHODS
We analyzed consecutive patients included in our stroke database who were treated with angioplasty alone. The subjects without major periprocedural complications were followed up for at least 42 months. Recurrent ischemic symptoms were defined as newly developed episodes of transient ischemic attack or ischemic stroke in the territory of the treated vessel. Stroke was defined as ischemic stroke in any vessel.
RESULTS
PTA was technically successful in 37 of the 40 included patients. Thirty-two of the 37 patients were followed up at regular intervals of 1 to 6 months in the outpatient clinic of our institution for at least 42 months. Restenosis occurred in 3 of the 32 patients (9.4%) within 2 years of PTA, and no restenosis was identified thereafter. Two of the three patients with restenosis had asymptomatic complications such as dissection and vasospasm during the intervention. The ischemic area was in the treated vessel in 1 of the 32 patients and in other vessels in 3 of the 32 patients (9.4%).
CONCLUSIONS
Successful PTA can result in a low rate of recurrent ischemic symptoms, and restenosis during a long-term follow-up appears to be more frequent in the early period.

Keyword

durability; angioplasty; middle cerebral artery; restenosis

MeSH Terms

Ambulatory Care Facilities
Angioplasty
Constriction, Pathologic
Follow-Up Studies
Glycosaminoglycans
Humans
Ischemic Attack, Transient
Middle Cerebral Artery
Stroke
Glycosaminoglycans

Figure

• 

  Fig. 1 Arterial patency after angioplasty excluding patients with significant postprocedural complications. The restenosis rate was 9.37% (3 of the 32 patients) within 2 years of PTA, and no restenosis was identified thereafter. PTA: percutaneous transminal angioplasty.

• 

  Fig. 2 Ischemic events occurring after successful PTA. The ischemic area was in the treated vessel in 1 of the 32 patients and in other vessels in 3 of the 32 patients. PTA: percutaneous transminal angioplasty.

Reference

1. Chimowitz MI, Lynn MJ, Howlett-Smith H, Stern BJ, Hertzberg VS, Frankel MR, et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N Engl J Med. 2005. 352:1305–1316.

2. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The northern Manhattan stroke study. Stroke. 1995. 26:14–20.

3. SSYLVIA Study Investigators. Stenting of symptomatic atherosclerotic lesions in the vertebral or intracranial arteries (SSYLVIA): study results. Stroke. 2004. 35:1388–1392.

4. Chimowitz MI, Kokkinos J, Strong J, Brown MB, Levine SR, Silliman S, et al. The warfarin-aspirin symptomatic intracranial disease study. Neurology. 1995. 45:1488–1493.

5. Thijs VN, Albers GW. Symptomatic intracranial atherosclerosis: outcome of patients who fail antithrombotic therapy. Neurology. 2000. 55:490–497.

6. Mori T, Mori K, Fukuoka M, Arisawa M, Honda S. Percutaneous transluminal cerebral angioplasty: serial angiographic follow-up after successful dilatation. Neuroradiology. 1997. 39:111–116.

7. Alazzaz A, Thornton J, Aletich VA, Debrun GM, Ausman JI, Charbel F. Intracranial percutaneous transluminal angioplasty for arteriosclerotic stenosis. Arch Neurol. 2000. 57:1625–1630.

8. Mazighi M, Yadav JS, Abou-Chebl A. Durability of endovascular therapy for symptomatic intracranial atherosclerosis. Stroke. 2008. 39:1766–1769.

9. Yoon W, Seo JJ, Cho KH, Kim MK, Kim BC, Park MS, et al. Symptomatic middle cerebral artery stenosis treated with intracranial angioplasty: experience in 32 patients. Radiology. 2005. 237:620–626.

10. Kappelle LJ, Eliasziw M, Fox AJ, Sharpe BL, Barnett HJ. Importance of intracranial atherosclerotic disease in patients with symptomatic stenosis of the internal carotid artery. The north American symptomatic carotid endarterectomy trail. Stroke. 1999. 30:282–286.

11. Demchuk AM, Christou I, Wein TH, Felberg RA, Malkoff M, Grotta JC, et al. Specific transcranial Doppler flow findings related to the presence and site of arterial occlusion. Stroke. 2000. 31:140–146.

12. Demchuk AM, Christou I, Wein TH, Felberg RA, Malkoff M, Grotta JC, et al. Accuracy and criteria for localizing arterial occlusion with transcranial Doppler. J Neuroimaging. 2000. 10:1–12.

13. Arenillas JF, Molina CA, Montaner J, Abilleira S, González-Sánchez MA, Alvarez-Sabín J. Progression and clinical recurrence of symptomatic middle cerebral artery stenosis: a long-term follow-up transcranial Doppler ultrasound study. Stroke. 2001. 32:2898–2904.

14. Wojak JC, Dunlap DC, Hargrave KR, DeAlvare LA, Culbertson HS, Connors JJ 3rd. Intracranial angioplasty and stenting: long-term results from a single center. AJNR Am J Neuroradiol. 2006. 27:1882–1892.

15. Fiorella D, Chow MM, Anderson M, Woo H, Rasmussen PA, Masaryk TJ. A 7-year experience with balloon-mounted coronary stents for the treatment of symptomatic vertebrobasilar intracranial atheromatous disease. Neurosurgery. 2007. 61:236–242. discussion 242-233.

16. Lee JH, Kwon SU, Lee JH, Suh DC, Kim JS. Percutaneous transluminal angi-oplasty for symptomatic middle cerebral artery stenosis: long-term follow-up. Cerebrovasc Dis. 2003. 15:90–97.

17. Marks MP, Marcellus M, Norbash AM, Steinberg GK, Tong D, Albers GW. Outcome of angioplasty for atherosclerotic intracranial stenosis. Stroke. 1999. 30:1065–1069.